| Trial ID: | L0476 |
| Source ID: | NCT03470961
|
| Associated Drug: |
Anti-Tlymphocyte Globulins
|
| Title: |
Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients
|
| Acronym: |
PAISPK
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
CKD (Chronic Kidney Disease) Stage 5T|Diabetes Mellitus|Simultaneous Pancreas Kidney Transplantation
|
| Interventions: |
DRUG: Anti-Tlymphocyte Globulins|DRUG: Anti-Thymocyte Globulins
|
| Outcome Measures: |
Primary: Incidence and severity of adverse event, Incidence of patient's death,graft loss,acute rejection, up to 3 months post-transplantation |
|
| Sponsor/Collaborators: |
Sponsor: Tianjin First Central Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
45
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2018-03-01
|
| Completion Date: |
2021-03-01
|
| Results First Posted: |
|
| Last Update Posted: |
2018-03-20
|
| Locations: |
Tianjin First central hospital, Tianjin, China
|
| URL: |
https://clinicaltrials.gov/show/NCT03470961
|
